Prestige Consumer Healthcare
PBH
47.57
+1.13
+2.43%
Prestige Consumer Healthcare
US · PBH
#2733 by market cap
Listed 1970
47.57
+1.13
+2.43%
Live - 5344 symbols - heartbeat 491s ago
· 2026-10-07 19:54
After-hours
47.57
0.00%
- Market cap
- 2.25B
- P/E (TTM)i
- 13.32
- P/Bi
- 1.18
- EPSi
- 3.91
- Div yieldi
- 0.00%
- 52W posi
- 17%
Reader sentiment
Are you bullish or bearish on PBH?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Fair
- Altman Z-Score is 2.25, in the 1.8-3.0 "grey zone".
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year -4.31% YoY
Margins
- Gross margin
- 54.71%
- Operating margin
- 28.42%
- Net margin
- 17.48%
Key ratios & quality
- Enterprise valuei
- 3.20B
- Altman Z-Scorei
- 2.25
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 975.78M | 963.01M | 943.37M | 1.09B | 1.13B | 1.13B | 1.14B | 1.09B |
| Gross profit | 555.58M | 552.22M | 547.47M | 620.65M | 625.29M | 624.45M | 634.46M | 595.58M |
| Selling & admin expenses | 462.31M | 236.31M | 223.70M | 264.80M | 252.42M | 259.47M | 263.93M | 265.23M |
| Research & development | -- | -- | -- | -- | -- | -- | -- | -- |
| Operating profit | 66.22M | 291.16M | 299.84M | 330.98M | 347.80M | 342.43M | 349.24M | 309.41M |
| Pretax profit | -38.06M | 191.15M | 204.11M | 262.46M | -93.92M | 276.03M | 284.19M | 257.50M |
| Tax | -2.26M | 48.87M | 39.43M | 57.08M | -11.61M | 66.69M | 69.58M | 67.20M |
| Net profit | -35.80M | 142.28M | 164.68M | 205.38M | -82.31M | 209.34M | 214.61M | 190.30M |
| Basic EPS | -1 | 3 | 3 | 4 | -2 | 4 | 4 | 4 |
| Diluted EPS | -0.69 | 2.78 | 3.25 | 4.04 | -1.65 | 4.17 | 4.29 | 3.91 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 296.52M | 249.53M | 274.11M | 283.44M | 281.62M | 265.71M |
| Gross profit | 170.01M | 140.33M | 151.58M | 157.37M | 146.30M | 136.19M |
| Selling & admin expenses | 64.05M | 63.39M | 66.74M | 69.73M | 65.37M | 77.97M |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | 100.89M | 71.76M | 79.67M | 82.49M | 75.49M | 52.52M |
| Pretax profit | 73.96M | 61.78M | 69.13M | 61.81M | 64.77M | 38.54M |
| Tax | 23.83M | 14.31M | 26.92M | 15.12M | 10.84M | 9.36M |
| Net profit | 50.13M | 47.47M | 42.21M | 46.70M | 53.93M | 29.18M |
| Basic EPS | 1 | 1 | 1 | 1 | 1 | 1 |
| Diluted EPS | 1.00 | 0.95 | 0.86 | 0.97 | 1.13 | 0.61 |
Balance sheet
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 300.94M | 365.65M | 269.84M | 293.27M | 391.74M | 375.04M | 448.33M | 431.48M |
| Cash & ST investments | 27.53M | 94.76M | 32.30M | 27.19M | 58.49M | 46.47M | 97.88M | 63.87M |
| Inventory | 119.88M | 116.03M | 114.96M | 120.34M | 162.12M | 138.72M | 147.71M | 159.13M |
| Total assets | 3.44B | 3.51B | 3.43B | 3.67B | 3.35B | 3.32B | 3.40B | 3.49B |
| Total current liabilities | 126.98M | 149.88M | 122.14M | 143.42M | 160.72M | 117.05M | 106.62M | 120.92M |
| Short-term debt | -- | 6.83M | 8.45M | 9.11M | 9.76M | 6.15M | 8.54M | 12.55M |
| Long-term debt | 1.80B | 1.73B | 1.48B | 1.48B | 1.35B | 1.13B | 992.36M | 993.95M |
| Total liabilities | 2,345,205,000.00 | 2,342,934,000.00 | 2,070,975,000.00 | 2,093,070,000.00 | 1,906,645,000.00 | 1,663,333,000.00 | 1,567,321,000.00 | 1,606,797,000.00 |
| Total equity | 1.10B | 1.17B | 1.36B | 1.58B | 1.45B | 1.66B | 1.83B | 1.89B |
| Retained earnings | 701.82M | 844.10M | 1.01B | 1.21B | 1.13B | 1.34B | 1.56B | 1.75B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 448.33M | 480.52M | 497.41M | 433.43M | 431.48M | 496.81M |
| Cash & ST investments | 97.88M | 139.50M | 119.11M | 62.37M | 63.87M | 89.13M |
| Inventory | 147.71M | 153.13M | 159.00M | 163.59M | 159.13M | 190.22M |
| Total assets | 3.40B | 3.43B | 3.44B | 3.49B | 3.49B | 4.57B |
| Total current liabilities | 106.62M | 109.67M | 134.60M | 139.56M | 120.92M | 153.81M |
| Short-term debt | 8.54M | 8.60M | 8.62M | 8.63M | 12.55M | 23.80M |
| Long-term debt | 992.36M | 992.75M | 993.15M | 1.03B | 993.95M | 2.01B |
| Total liabilities | 1,567,321,000.00 | 1,576,143,000.00 | 1,617,311,000.00 | 1,665,292,000.00 | 1,606,797,000.00 | 2,651,857,000.00 |
| Total equity | 1.83B | 1.86B | 1.82B | 1.83B | 1.89B | 1.92B |
| Retained earnings | 1.56B | 1.60B | 1.65B | 1.69B | 1.75B | 1.78B |
Cash flow
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 189.28M | 217.12M | 235.61M | 259.92M | 229.72M | 248.93M | 251.52M | 257.63M |
| Depreciation & amortization | 31.78M | 29.00M | 30.16M | 32.09M | 32.63M | 30.68M | 30.17M | 31.27M |
| Free cash flow | 178.80M | 202.56M | 213.36M | 250.28M | 221.93M | 239.38M | 243.29M | 246.45M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -49.98M | -56.72M | -11.87M | 0 | -50.00M | -25.00M | -51.51M | -156.28M |
| Ending cash balance | 27.53M | 94.76M | 32.30M | 27.19M | 58.49M | 46.47M | 97.88M | 63.87M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 61.85M | 79.01M | 57.49M | 78.29M | 42.84M | 70.79M |
| Depreciation & amortization | 7.25M | 7.67M | 7.66M | 7.59M | 8.35M | 8.75M |
| Free cash flow | 58.37M | 78.18M | 55.38M | 75.26M | 37.63M | 67.09M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -11.31M | -34.78M | -75.00M | -45.82M | -690.00K | 0 |
| Ending cash balance | 97.88M | 139.50M | 119.11M | 62.37M | 63.87M | 89.13M |
Returns & efficiency
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -3.15 | 12.55 | 13.02 | 13.99 | -5.44 | 13.50 | 12.30 | 10.22 |
| ROA %i | -0.99 | 4.09 | 4.74 | 5.79 | -2.34 | 6.28 | 6.39 | 5.52 |
| ROIC %i | 2.08 | 7.33 | 7.96 | 8.59 | -0.74 | 9.28 | 8.83 | 7.63 |
| 5-year avg ROE %i | 13.47 | 13.35 | 13.04 | 14.07 | 6.20 | 9.52 | 9.47 | 8.91 |
| EBIT margin %i | 6.89 | 29.88 | 30.36 | 30.06 | -2.19 | 30.50 | 29.16 | 27.54 |
| FCF / sales %i | 18.32 | 20.75 | 22.62 | 23.03 | 19.68 | 21.27 | 21.38 | 22.64 |
| Current ratioi | 2.37 | 2.44 | 2.21 | 2.04 | 2.44 | 3.20 | 4.20 | 3.57 |
| Quick ratioi | 1.39 | 1.64 | 1.20 | 1.16 | 1.40 | 1.91 | 2.74 | 2.12 |
| Debt / assetsi | 52.27 | 50.28 | 44.17 | 41.04 | 40.76 | 34.34 | 30.69 | 29.92 |
| LT debt / equityi | 164.13 | 150.29 | 110.89 | 94.91 | 93.80 | 68.49 | 56.45 | 54.72 |
| Interest coveragei | 0.64 | 2.98 | 3.48 | 5.08 | -0.36 | 5.11 | 6.97 | 7.08 |
| Revenue CAGR (3Y) %i | 6.57 | 2.97 | -3.24 | 3.66 | 5.40 | 6.06 | 1.54 | -1.17 |
| Net income CAGR (3Y) %i | -- | 27.04 | -21.43 | -- | -- | 8.33 | 1.48 | -- |
| FCF CAGR (3Y) %i | 1.16 | 11.61 | 2.60 | 11.86 | 3.09 | 3.91 | -0.94 | 3.55 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 12.30 | 12.05 | 11.29 | 10.31 | 10.22 | 9.12 |
| ROA %i | 6.39 | 6.32 | 5.94 | 5.47 | 5.52 | 4.30 |
| ROIC %i | 8.83 | 8.66 | 8.16 | 7.53 | 7.63 | 5.98 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 29.16 | 29.66 | 29.49 | 27.94 | 27.54 | 25.37 |
| FCF / sales %i | 21.38 | 23.91 | 23.00 | 24.21 | 22.64 | 21.30 |
| Current ratioi | 4.20 | 4.38 | 3.70 | 3.11 | 3.57 | 3.23 |
| Quick ratioi | 2.74 | 2.81 | 2.36 | 1.81 | 2.12 | 1.80 |
| Debt / assetsi | 30.69 | 30.39 | 30.24 | 30.88 | 29.92 | 45.25 |
| LT debt / equityi | 56.45 | 55.73 | 56.57 | 58.52 | 54.72 | 106.62 |
| Interest coveragei | 6.97 | 7.43 | 7.71 | 7.40 | 7.08 | 6.08 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Single-engine
- North American over-the-counter (OTC) Healthcare is the largest reported line at 85.40% of revenue, across 3 reported segments.
- The next-largest line, International over-the-counter (OTC) Healthcare, is a distant second at 14.87% - a sharp slowdown here would have little to offset it.
Revenue breakdown most recent period
Business
North American over-the-counter (OTC) Healthcare85.40%
International over-the-counter (OTC) Healthcare14.87%
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.